tradingkey.logo

Synergy CHC Corp

SNYR
1.770USD
+0.050+2.91%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
19.92MMarktkapitalisierung
6.29KGV TTM

Synergy CHC Corp

1.770
+0.050+2.91%

mehr Informationen über Synergy CHC Corp Unternehmen

Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications.

Synergy CHC Corp Informationen

BörsenkürzelSNYR
Name des UnternehmensSynergy CHC Corp
IPO-datumNov 08, 2013
CEORoss (Jack)
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeNov 08
Addresse865 Spring St
StadtWESTBROOK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl04092-3828
Telefon16159399004
Websitehttps://synergychc.com/
BörsenkürzelSNYR
IPO-datumNov 08, 2013
CEORoss (Jack)

Führungskräfte von Synergy CHC Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jack Ross
Mr. Jack Ross
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
674.81K
+11100.00%
Mr. J. Paul SoRelle
Mr. J. Paul SoRelle
Independent Director
Independent Director
--
--
Ms. Jaime Fickett
Ms. Jaime Fickett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alfred Baumeler
Mr. Alfred Baumeler
President, Director
President, Director
--
--
Mr. Nitin Kaushal, CPA
Mr. Nitin Kaushal, CPA
Independent Director
Independent Director
--
--
Ms. Teresa Thompson
Ms. Teresa Thompson
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jack Ross
Mr. Jack Ross
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
674.81K
+11100.00%
Mr. J. Paul SoRelle
Mr. J. Paul SoRelle
Independent Director
Independent Director
--
--
Ms. Jaime Fickett
Ms. Jaime Fickett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alfred Baumeler
Mr. Alfred Baumeler
President, Director
President, Director
--
--
Mr. Nitin Kaushal, CPA
Mr. Nitin Kaushal, CPA
Independent Director
Independent Director
--
--
Ms. Teresa Thompson
Ms. Teresa Thompson
Director
Director
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q3
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Nutraceuticals
8.01M
0.00%
Licenses revenue
0.00
0.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
7.08M
88.36%
Foreign countries
932.46K
11.64%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Nutraceuticals
8.01M
0.00%
Licenses revenue
0.00
0.00%

Aktionärsstatistik

Aktualisiert: Sat, Jan 10
Aktualisiert: Sat, Jan 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Gowan Private Equity, Inc.
32.70%
Knight Therapeutics (Barbados), Inc.
13.18%
Ross (Jack)
6.00%
Gratia Capital, LLC
4.93%
Heartland Advisors, Inc.
4.89%
Andere
38.31%
Aktionäre
Aktionäre
Anteil
Gowan Private Equity, Inc.
32.70%
Knight Therapeutics (Barbados), Inc.
13.18%
Ross (Jack)
6.00%
Gratia Capital, LLC
4.93%
Heartland Advisors, Inc.
4.89%
Andere
38.31%
Aktionärstypen
Aktionäre
Anteil
Corporation
49.49%
Individual Investor
6.97%
Hedge Fund
5.23%
Investment Advisor/Hedge Fund
5.13%
Investment Advisor
0.86%
Research Firm
0.14%
Andere
32.18%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
20
1.28M
11.36%
+122.47K
2025Q3
15
489.86K
4.38%
-692.44K
2025Q2
20
7.35M
81.54%
-158.23K
2025Q1
20
7.51M
86.32%
+3.84M
2024Q4
17
7.37M
84.73%
+5.72M
2024Q3
6
504.50K
6.68%
-5.50M
2024Q2
6
6.00M
79.48%
+6.00M
2023Q3
6
5.96M
78.91%
--
2023Q2
6
5.96M
78.91%
--
2023Q1
6
5.96M
78.91%
--
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Gowan Private Equity, Inc.
3.68M
32.7%
--
--
Apr 21, 2025
Knight Therapeutics (Barbados), Inc.
1.48M
13.18%
--
--
Jun 11, 2025
Ross (Jack)
674.81K
6%
+11.10K
+1.67%
Jul 30, 2025
Gratia Capital, LLC
555.00K
4.93%
+555.00K
--
Sep 30, 2025
Heartland Advisors, Inc.
550.00K
4.89%
+550.00K
--
Sep 30, 2025
Dunhill Distribution Group, Inc.
269.63K
2.4%
--
--
Apr 21, 2025
Gowan Capital, Inc.
136.56K
1.21%
--
--
Apr 21, 2025
SoRelle (James Paul)
108.96K
0.97%
--
--
Apr 21, 2025
The Vanguard Group, Inc.
66.01K
0.59%
+43.87K
+198.22%
Sep 30, 2025
Warberg Asset Management LLC
33.52K
0.3%
+33.52K
--
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI